Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid‐Free Analgesics
Open Access
- 14 October 2024
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 63 (47) , e202405941
Abstract
The opioid crisis has highlighted the urgent need to develop non‐opioid alternatives for managing pain, with an effective, safe, and non‐addictive pharmacotherapeutic profile. Using an extensive structure–activity relationship approach, here we have identified a new series of highly selective neurotensin receptor type 2 (NTS2) macrocyclic compounds that exert potent, opioid‐independent analgesia in various experimental pain models. To our knowledge, the constrained macrocycle in which the Ile12 residue of NT(7–12) was substituted by cyclopentylalanine, Pro7 and Pro10 were replaced by allyl‐glycine followed by side‐chain to side‐chain cyclization is the most selective analog targeting NTS2 identified to date (Ki 2.9 nM), showing 30,000‐fold selectivity over NTS1. Of particular importance, this macrocyclic analog is also able to potentiate the analgesic effects of morphine in a dose‐ and time‐dependent manner. Exerting complementary analgesic actions via distinct mechanisms of nociceptive transmission, NTS2‐selective macrocycles can therefore be exploited as opioid‐free analgesics or as opioid‐sparing therapeutics, offering superior pain relief with reduced adverse effects to pain patients.Keywords
Funding Information
- Canadian Institutes of Health Research (FDN-148413)
This publication has 91 references indexed in Scilit:
- Opening the amino acid toolbox for peptide‐based NTS2‐selective ligands as promising lead compounds for pain managementJournal of Peptide Science, 2023
- The Hidden Epidemic of Opioid Overdoses During the Coronavirus Disease 2019 PandemicJAMA Psychiatry, 2021
- The Opioid Epidemic During the COVID-19 PandemicJAMA, 2020
- Changes in Synthetic Opioid Involvement in Drug Overdose Deaths in the United States, 2010-2016JAMA, 2018
- Practical Medicinal Chemistry with Macrocycles2017
- Overview of Macrocycles in Clinical Development and Clinically Used2017
- Structure‐Based Evolution of Subtype‐Selective Neurotensin Receptor LigandsChemistryOpen, 2014
- Conformational constraint in protein ligand design and the inconsistency of binding entropyBiopolymers, 2008
- Selective Neurotensin-Derived Internally Quenched Fluorogenic Substrates for Neurolysin (EC 3.4.24.16): Comparison with Thimet Oligopeptidase (EC 3.4.24.15) and Neprilysin (EC 3.4.24.11)Analytical Biochemistry, 2001
- The role of excitatory amino acid receptors and intracellular messengers in persistent nociception after tissue injury in ratsMolecular Neurobiology, 1993